The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
17-alpha-Hydroxyprogesterone inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]
17-alpha-Hydroxyprogesterone results in increased activity of AR protein 17-alpha-Hydroxyprogesterone inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]
CYP17A1 protein affects the abundance of 17-alpha-Hydroxyprogesterone CYP17A1 protein affects the chemical synthesis of 17-alpha-Hydroxyprogesterone CYP17A1 protein affects the metabolism of 17-alpha-Hydroxyprogesterone [[abiraterone results in decreased activity of CYP17A1 protein] which results in decreased hydroxylation of Progesterone] which results in increased chemical synthesis of 17-alpha-Hydroxyprogesterone; [CYP17A1 protein results in increased hydroxylation of Progesterone] which results in increased chemical synthesis of 17-alpha-Hydroxyprogesterone; [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone] which results in increased chemical synthesis of Androstenedione; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased hydroxylation of Progesterone] which results in increased chemical synthesis of 17-alpha-Hydroxyprogesterone]; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone] which results in increased chemical synthesis of Androstenedione]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone]; TNF protein inhibits the reaction [CYP17A1 protein affects the metabolism of 17-alpha-Hydroxyprogesterone]; Venlafaxine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased hydroxylation of Progesterone] which results in increased chemical synthesis of 17-alpha-Hydroxyprogesterone]; Venlafaxine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone] which results in increased chemical synthesis of Androstenedione]; Venlafaxine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone]
[17-alpha-Hydroxyprogesterone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein
17-alpha-Hydroxyprogesterone inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; [17-alpha-Hydroxyprogesterone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein
browse the term
